#osicent

[iebpharma1]

Introduction to Osicent 80 mg (Osimertinib)

Osicent 80 mg, the brand name for osimertinib, is an advanced targeted therapy used in the treatment of certain types of non-small cell lung cancer (NSCLC). It falls under the category of epidermal growth factor receptor (EGFR) inhibitors, specifically designed to block the activity of a mutated EGFR protein that is involved in the growth and spread of cancer cells. This medication has revolutionized the treatment of EGFR-mutated lung cancer and is widely utilized for its efficacy in managing advanced stages of cancer, particularly in patients with mutations resistant to other EGFR inhibitors.

Mechanism of Action

Osicent 80 mg (Osimertinib) works by targeting and inhibiting the activity of EGFR that has specific mutations, such as the T790M resistance mutation. EGFR mutations are common in patients with NSCLC, and they often result in the uncontrolled growth of cancer cells. Osimertinib specifically binds to and blocks the EGFR protein, effectively preventing cancer cells from proliferating. By doing so, osimertinib not only helps to stop tumor growth but also promotes cancer cell death, improving the overall prognosis of individuals diagnosed with advanced lung cancer.

Unlike earlier-generation EGFR inhibitors, Osicent 80 mg is designed to be effective against both the common EGFR mutations and the T790M mutation, which often leads to resistance to other treatments. This makes Osicent 80 mg (Osimertinib) an ideal treatment option for patients who have already undergone EGFR-targeted therapy and experienced disease progression.

Indications for Use

Osicent 80 mg is primarily prescribed for patients diagnosed with non-small cell lung cancer who have specific EGFR mutations. The primary indications for the use of Osicent 80 mg include:

First-line treatment of metastatic non-small cell lung cancer (NSCLC) with EGFR mutations: Osicent is used as a first-line therapy in patients who have metastatic NSCLC with exon 19 deletions or exon 21 L858R mutations.

Treatment of NSCLC with T790M mutation: Osicent is highly effective in patients who have acquired resistance to prior EGFR inhibitors due to the T790M mutation, making it a critical option for second-line treatment.

Adjuvant treatment: In some cases, Osicent is prescribed for patients in the adjuvant setting (following surgery) to reduce the risk of cancer recurrence, especially if the tumor has EGFR mutations.

Dosage and Administration

Osicent 80 mg is administered orally, typically once a day, with or without food. The standard dosage is one tablet of 80 mg per day, and the treatment may continue as long as the patient is benefiting from it and can tolerate the medication. In cases of adverse effects, the dose may be adjusted under the guidance of a healthcare provider.

Potential Side Effects

While Osicent 80 mg has been shown to be highly effective in treating NSCLC, like any medication, it can cause side effects. Common side effects include:

Diarrhea: One of the most frequently reported side effects, which can be managed with supportive care.

Rash: A skin rash may develop, often resembling acne, which is common with EGFR inhibitors.

Fatigue: Some patients experience tiredness or weakness during treatment.

Nausea: Although less common, nausea may occur, particularly during the initial phases of treatment.

Interstitial lung disease (ILD): A more serious, though less frequent, side effect is the development of ILD, which causes inflammation in the lungs and requires immediate medical attention.

Most side effects are manageable, and many patients find that the benefits of treatment outweigh the risks, particularly when the drug is effective in controlling cancer growth.

Precautions and Warnings

Before starting Osicent 80 mg, patients should inform their healthcare provider of any pre-existing lung or heart conditions. It is essential to monitor lung function regularly, as some patients may experience pulmonary issues during treatment. Additionally, Osicent can interact with other medications, so it’s crucial to inform the healthcare provider about any other drugs being taken, including over-the-counter medications and supplements.

Pregnant or breastfeeding women should avoid taking Osicent, as it could harm the fetus or infant. The safety of osimertinib in pediatric patients has not been established, so it is generally not recommended for use in children.

Conclusion

Osicent 80 mg (Osimertinib) has significantly changed the landscape of treatment for patients with EGFR-mutated non-small cell lung cancer. As a targeted therapy, it provides a precise and effective option for individuals whose cancer is resistant to other treatments. Its ability to target specific mutations, including the T790M mutation, has made it a vital part of lung cancer management. Patients prescribed Osicent can experience better outcomes, particularly in advanced or metastatic stages of cancer, leading to improved survival rates and quality of life.

As with any cancer treatment, it is crucial for patients to work closely with their healthcare providers to monitor their response to the medication and manage any potential side effects. With continued research and development, the role of Osicent 80 mg in cancer treatment is expected to grow, offering hope to many facing EGFR-mutated non-small cell lung cancer.

[pybun]

very proud of this stupid idea

[page-2-ids]

[ID: A flag with five horizontal stripes, all the same size. The colors get lighter towards the middle and darker towards the edges. The colors are, from top to bottom, black, washed-out maroon, washed-out magenta, washed-out dark purple, and black. END ID]

Demonosic: A gender related to demon personalities/personality traits

The colors are inspired by flags for various demon-related genders

No Suggested Pronouns

[paintingpuff]

for someone trying to quit the OSIC she keeps talking like a fed

[maidfrin]

your post reminded me of the time in spite i taught my psych ward friends what mogai was bc the staff kept getting angry at "made up genders" (i was a ftm trans guy at the time identifying) and half the unit was some -osic at the end it was fucking hilarious bc they kept getting so worked up at every new gender we'd make. someone was peppapiggender at the end

forgot to answer this one. this fucking rules

[justinspoliticalcorner]

David Badash at NCRM:

A little-known but far-reaching office within the U.S. Department of Homeland Security has removed protections for LGBTQ+ people from a policy that restricted intelligence gathering on certain groups, following an executive order from President Donald Trump to dismantle diversity, equity, and inclusion (DEI) policies. The DHS Office of Intelligence and Analysis (I&A), one of 18 organizations that comprise the U.S. intelligence community—now overseen by Director of National Intelligence Tulsi Gabbard—reportedly has long faced allegations of civil liberties and civil rights abuses. The Office of Intelligence and Analysis (I&A) has stripped the words “gender identity” and “sexual orientation” from a policy manual “that set guardrails on gathering intelligence,” Bloomberg Government first reported. “I&A’s work has attracted close scrutiny for years because of its domestic focus, with intelligence often involving US citizens and others in the country.” According to The Advocate, an archived version of the text previously read: “OSIC Personnel are prohibited from engaging in intelligence activities based solely on an individual’s or group’s race, ethnicity, gender, religion, sexual orientation, gender identity, country of birth, nationality, or disability. The use of these characteristics is permitted only in combination with other information, and only where (1) intended and reasonably believed to support one or more of I&A’s national or departmental missions and (2) narrowly focused in support of that mission (or those missions).”

The words “sexual orientation” and “gender identity” have since been removed. “The Office of Intelligence & Analysis (I&A) is a unique member of the U.S. Intelligence Community (IC),” the office states on its homepage within the DHS domain. “I&A is the only IC element statutorily charged with delivering intelligence to our State, Local, Tribal and Territorial (SLTT) and private sector partners, and developing intelligence from those partners for the Department and the IC.”

The DHS’s Office of Intelligence and Analysis under Kristi Noem is waging war on the LGBTQ+ community by removing sexual orientation and gender identity from a policy that restricted intelligence gathering on certain groups. Such a move is an act of heinous anti-LGBTQ+ bigotry mirroring Hungary, Turkey, and Russia.

See Also:

LGBTQ Nation: Homeland Security can now spy on LGBTQ+ people & groups as threats to U.S. safety

The Advocate: DHS quietly eliminates ban on surveillance based on sexual orientation and gender identity

[iebpharma1]

How Osicent 80 mg Works

Osicent 80 mg, which contains the active ingredient Osimertinib, is a medication primarily used for the treatment of certain types of non-small cell lung cancer (NSCLC). It falls under the category of targeted therapies, designed to treat specific genetic mutations in cancer cells. Osimertinib, marketed under various brand names, is an effective option for patients whose cancers have specific mutations or are resistant to other treatments.

How Osicent 80 mg Works

Osicent works by targeting a mutation in the epidermal growth factor receptor (EGFR), which is often found in NSCLC. EGFR is a protein that plays a key role in cell growth. In cancer cells, mutations in the EGFR gene can lead to uncontrolled growth and division of the cells. Osicent 80 mg (Osimertinib) is classified as an EGFR tyrosine kinase inhibitor (TKI), meaning that it blocks the abnormal signals that promote cancer cell growth. Specifically, it is used in the treatment of NSCLC with EGFR T790M mutations, which are known to cause resistance to earlier generations of EGFR inhibitors.

This medication is particularly notable for its ability to target the exon 19 deletion and L858R mutation of the EGFR gene, in addition to the T790M mutation. By blocking these mutations, Osicent prevents the EGFR signaling pathway, inhibiting cancer cell proliferation and inducing cancer cell death, which ultimately helps control the progression of the cancer.

Indications and Usage

Osicent 80 mg is indicated for:

Advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or L858R mutations: These mutations are common in certain lung cancers and often respond to EGFR inhibitors.

EGFR T790M mutation-positive NSCLC: Osimertinib is particularly effective for patients who have developed resistance to first- and second-generation EGFR inhibitors. The T790M mutation is a common resistance mutation.

Adjuvant treatment: Osicent is sometimes used as an adjuvant therapy to prevent recurrence in early-stage EGFR mutation-positive lung cancer after surgery.

Dosage and Administration

The recommended dosage of Osicent 80 mg is typically one tablet per day, taken orally. It can be taken with or without food, but it is crucial to take the medication at the same time each day to ensure consistent levels in the body.

In cases of side effects or treatment response issues, dosage adjustments may be necessary. It is important that patients follow the prescribing physician's instructions regarding dosage and administration.

Side Effects

Like all medications, Osicent 80 mg can cause side effects. Not everyone will experience these side effects, and some people may experience them to a lesser extent. Common side effects include:

Diarrhea: This is one of the most common side effects and may require additional treatment to manage.

Rash: A skin rash may develop in some patients, which could be a sign of the body’s immune response to the medication.

Dry skin or itchiness: Some patients may experience dry or irritated skin.

Fatigue: Feelings of tiredness or weakness may occur during treatment.

Nausea: Mild nausea is sometimes reported, which can be managed with dietary adjustments or anti-nausea medications.

Appetite loss: Some patients may experience a decrease in appetite.

Lung problems: Serious side effects may include lung inflammation, which can cause difficulty breathing, cough, or fever. If any breathing difficulties occur, the patient should seek immediate medical attention.

In rare cases, Osicent may cause more severe side effects, such as heart problems, eye problems, or severe allergic reactions. Monitoring by a healthcare provider is important during the treatment to ensure safety and manage any adverse reactions promptly.

Precautions and Warnings

Before starting Osicent treatment, patients should inform their doctor of:

Pre-existing lung conditions: Such as chronic obstructive pulmonary disease (COPD), asthma, or any history of interstitial lung disease (ILD).

Heart conditions: Since Osicent has been associated with QT prolongation, a heart condition that can lead to serious arrhythmias.

Eye issues: Eye problems, including vision disturbances, should be disclosed.

Pregnancy and breastfeeding: Osicent is not recommended during pregnancy or breastfeeding unless absolutely necessary. It is important to discuss any potential risks with the healthcare provider.

Regular monitoring of heart function and lung health is important while on Osicent, as it can lead to complications in some patients.

Global Medicine Services and Trust

Osicent 80 mg, manufactured by reputed pharmaceutical companies, is available through licensed distributors around the world. Medicine services, such as these, ensure that the medication is sourced from trusted suppliers and delivered to patients in compliance with regulatory standards. The global availability of Osicent represents the commitment to providing advanced cancer treatments to people across various countries.

Patients and healthcare providers worldwide have trusted Osicent for its efficacy in managing EGFR-positive lung cancer. This treatment has significantly improved the quality of life for many patients, offering hope for those facing a challenging diagnosis. Access to reliable, high-quality medicine services is crucial, and Osicent 80 mg plays a key role in delivering advanced cancer care globally.

Conclusion

Osicent 80 mg (Osimertinib) is a groundbreaking treatment option for patients with EGFR mutation-positive non-small cell lung cancer, particularly those who have developed resistance to previous therapies. With its targeted action and relatively manageable side effect profile, Osicent has become a cornerstone in the treatment of advanced lung cancer. As with all cancer therapies, patient monitoring and a personalized treatment plan are critical to maximizing benefits and minimizing risks.

[tedloveshisbed]

🖥️🕹️ FORTUNE-9 OSic/FORTUNE9ic -- A gender relating to the Lethal Company terminal, Fortune-9.

The flag's stripes represent the shell of the terminal, ranging from beige to grey, and green triangles represent the green test that the terminal uses.

coined by me!!!

[pybun]

a quick script of the comic im thinking with dynamo, abrams and marlowe. looks like this will exceed 6 pages if i also wanna do the lunch date scene

for some context: haze got a bunch of new lines and her lines for dynamo implies that his wife, marlowe, is at least one of the heads of the OSIC that haze works for

PAGE 1-------------------------------

1 - library exterior night

2 - abrams hiding in the shadows outside library 3 - close up on his watch showing its around 11pm 4 - worried abrams face

5 - tapping of footsteps can be heard, abrams turns around to see whos appraoching him 6 - dynamos running towards him with the book in hand

PAGE 2-------------------------------

1 - dynamo info dumps abt his access to the nocturnal library 2 - abrams looks worried but also flustered 3 - abrams tunnel visioning onto dynamo's "eyes" while dynamo kept yapping

4 - abrams pins dynamo on the nearest wall, stopping dynamo from talking

5 - dynamo: w-what's wrong? 6 - abrams staring, sweating, trying to come up with words. background is filled with words he wanted to say (he was v worried that he might gotten attacked in there, etc) 7 - dyn: sorry. i shouldn't have spilled. haha. wrong place and time. s-sorry

8 - abrams, embarassed: y-yeah…..lets go some place safe

PAGE 3-------------------------------

1 - dyn: oh i have to go home. marlowe might be worried sick 2 - abrams, looking away: oh y-yeah sure. i'll just call you tomorrow 3 - dynamo hands abrams some papers dyn: here, i made a photocopy of the notes i took

4 - abrams: thank you, dynamo. i really appreciate all the help 5 - dyn: its a pleasure! see you tomorrow or whenever

6 - wide shot of library front, the 2 are splitting up. theres a car in the foreground

7 - car interior shot. close up on screen on dashboard showing OSIC logo driver: isn't that your husband, maam 8 - pull back shot, someones sitting at the backseat looking out the window marlowe: unmistakably

(might combine 7 and 8 panels to make room for 9)

9 - close up of marlowe looking neutral driver: that other man- marlowe: lets just leave driver: of course

PAGE 4-------------------------------

1 - wide shot of bed room. marlowe is already in bed "asleep". dynamo enters the room

2 - dynamo in his jammies, getting ready and sitting on the bed next to his wife 3 - marlowe turns around to face her husband 4 - back, close up shot of dynamo noticing marlowe marlowe, offscreen: how was work today?

5 - dynamo while slipping under the blanket: i was helping a friend with some research after work. sorry, i didnt expect it would take that long mar, listening: what did you guys find? 6 - dynamo, settled in bed, facing marlowe dyn: remember the nocturnal library ive heard about? i finally got in! [info dump] 7 - marlowe, listening, smiling

PAGE 5-------------------------------

1 - mar: whos the friend youre helping? dyn: it's detective abrams. he's a bit obsessed with this book but i don't mind….i mean it is interesting to look into and look where it got me today 2 - marlowe's face relaxed, holding back a thought for a moment 3 - dynamo looks at marlowe as she started speaking mar: remember what i said years ago that, due to the nature of my work, i wouldnt hate you if you find company in other people?

4 - dynamo shot up in bed dyn, embarassed: no no no, that's not where this book thing is going- 5 - dynamo pauses, relaxes and realized dyn: you were there were you? at the library?

6 - marlowe, lies on her back to face away from her husband, looking at the ceiling mar: my position is not usually concerned of who gets access to the nocturnal library but when i was notified that a familiar name showed up, i had to see it for myself

7 - dynamo looking at her still facing the ceiling 8 - same panel but dynamo facing away, kinda defeated dyn: there's nothing going on between me and the detective 9 - same panel again, now marlowe looking at dynamo mar: have you asked the detective? 10 - same panel again but wider, dynamo meets marlowe's gaze

[rip-osic]

sigilism

by me

[page-2-ids]

[ID: A flag with five horizontal stripes, the first is twice the height of the others. The colors get lighter towards the fourth stripe and darker towards the edges. The colors are, from top to bottom, black, maroon, dark red-pink, lavender, and indigo. END ID]

Vamposic: A gender related to vampire personalities/personality traits

The colors are inspired by flags for various vampire-related genders

No Suggested Pronouns

[calcedon79]

WIP GAME

@charmwasjess I found a snippet of a little story for your 2024 preview wip game. *****

There were thousands of planets in the galaxy. The chance of running into each other somewhere? Vanishingly small.

But not even two years after their first encounter, the newly minted Padawan Sifo-Dyas and the Mandalorian Jaster Mereel met again.

On a rather remote planet.

In a cave.

A cave in which Jaster had accidentally woken up a cave dragon.

A very bad-tempered dragon that was now chasing the two eleven- and twelve-year-olds through the underground passages.

"What are you doing here anyway?" gasped Jaster, dodging a toppling stalactite. Stupid animal. Why couldn't it have just gone back to sleep? Jaster hadn't made that much noise. (Admittedly, if someone jumped on his head during his nap, he'd probably be in a bad mood too).

"I wrote to you the other day: I'm exploring abandoned ruins for ancient Jedi artifacts with my master," the other boy called out. He dropped as a scaly tail smashed into the rocks above him, sending small stones hurtling through the cave.

"The ruins are on the surface, di'kut!" shouted Jaster back, "Duck!"

"True." The other boy nimbly changed direction and caught up with Jaster. "Broke through the ceiling at one point and landed down here. TO THE LEFT." He grabbed the Mandalorian boy by the wrist and yanked him along. "And you?"

"Ba'buir let me look around while she replaces some faulty stabilizers," the Mandalorian boy gasped.

"Down here?" Sy blinked at him through the dusty strands of hair that hung in his face. Jaster wondered why his friend hadn't run into something long ago. Force-osic, probably.

"Broke in, too." He shrugged his shoulders. "Which way now?"

"That way up ahead." Sy pointed to the side. "Maybe the critter can't get through there."

Unfortunately, the narrow passage was no obstacle for a bad-tempered lizard. An angry roar filled the air as it blasted its way through with its body mass.

"Kriff! Now what?!"

"We could turn around and attack it."

"Are you crazy?!" Sifo-Dyas shot him a horrified look. "The beast has a mouth full of sharp teeth at the front and is only vulnerable on its belly. Besides, my lightsaber is lying upstairs in the crypt."

"You didn't bring another weapon?" Jaster's indignation was audible even over the racket.

"And where's your blaster, Mando?" the Minasheejedi hissed back. "I don't see you shooting."

"Uhh… fell out of my hand when I landed."

And that was that.

[sunskate]

tw:

thank you for this info. both of these are very much worth the time. oooof. the W5 documentary - my heart hurts for those girls and women. it's harrowing even to read the transcript. i started watching and had to stop and read the rest. completely devastating. and at the same time infuriating

the Future of Figure Skating podcast - the process in Canada very much sounds like it shields the institutions and therefore the abusers during investigation. Amelia Cline says they've found that going outside the systems in place is often the most effective route. which is damning about the system. Abby Spadafora says complaints often aren't taken seriously, or can be kicked around from Office of Sport Integrity Commissioner (OSIC) to the National or provincial sporting organization. they've had cases where the person reporting the abuse was put in the same room with their abuser to recount their complaint. horrific stuff. independent investigators who have conflicts of interest or are otherwise unsuited to the task, the list goes on

not only is the process itself and the timeline not made clear by OSIC to the parties involved, OSIC has strict confidentiality clauses that keep people from speaking while the process is ongoing. once a case is brought, there might be news stories in the beginning, but then there's silence because of this. no further bad press for the abuser or the institutions involved. and the victims can't speak about their own experiences for fear that it will be used against them in the case. they're saying that if you were involved in a criminal case, you'd have more right to speak than in these OSIC cases. [so this could be why we haven't heard more in the Soerensen case]

they said the solution is to treat these like any other human rights issues - in any other circumstance, it wouldn't be this hard to fire and remove adults abusing children. that the process needs to be consistent and more transparent and public. that there needs to be a top down, bottom up reassessment of the entire system so it can be figured out where and how it's broken. they started out investigating gymnastics and found the same stories in so many other sports - that it's an issue in all sport

OSIC was modeled after the US Center for Safe Sport which is a system they have no confidence in. this is an in depth discussion where they bring up so many facets - like how it would be important for role models and more of the public to speak up, to say they believe survivors - and not just the famous ones - when these survivors risk so much in speaking out